A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models

  1. Yuhan Zhao
  2. Lihua Wu
  3. Xuetian Yue
  4. Cen Zhang
  5. Jianming Wang
  6. Jun Li
  7. Xiaohui Sun
  8. Yiming Zhu
  9. Zhaohui Feng
  10. Wenwei Hu  Is a corresponding author
  1. Rutgers, The State University of New Jersey, United States
  2. Zhejiang University, China

Abstract

Tumor suppressor p53 prevents early death due to cancer development. However, the role of p53 in aging process and longevity has not been well-established. In humans, single nucleotide polymorphism (SNP) with either arginine (R72) or proline (P72) at codon 72 influences p53 activity; the P72 allele has a weaker p53 activity and function in tumor suppression. Here, employing a mouse model with knock-in of human TP53 gene carrying codon 72 SNP, we found that despite increased cancer risk, P72 mice that escape tumor development display a longer lifespan than R72 mice. Further, P72 mice have a delayed development of aging-associated phenotypes compared with R72 mice. Mechanistically, P72 mice can better retain the self-renewal function of stem/progenitor cells compared with R72 mice during aging. This study provides direct genetic evidence demonstrating that p53 codon 72 SNP directly impacts aging and longevity, which supports a role of p53 in regulation of longevity.

Article and author information

Author details

  1. Yuhan Zhao

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5529-1907
  2. Lihua Wu

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Xuetian Yue

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Cen Zhang

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Jianming Wang

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jun Li

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Xiaohui Sun

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Yiming Zhu

    Department of Epidemiology and Biostatistics, Zhejiang University, Hangzhou, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Zhaohui Feng

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Wenwei Hu

    Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States
    For correspondence
    wh221@cinj.rutgers.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3971-4257

Funding

Lawrence Ellison Foundation (New Investigate Award AG-NS-0781-11)

  • Wenwei Hu

National Institutes of Health (1R01CA160558)

  • Wenwei Hu

National Institutes of Health (1R01CA203965)

  • Wenwei Hu

National Institutes of Health (F99CA222734)

  • Yuhan Zhao

National Institutes of Health (1R01CA227912)

  • Zhaohui Feng
  • Wenwei Hu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animal experiments were approved by institutional animal care and use committee (IACUC) protocol (I14-012) of the University of Rutgers.

Copyright

© 2018, Zhao et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,252
    views
  • 564
    downloads
  • 40
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yuhan Zhao
  2. Lihua Wu
  3. Xuetian Yue
  4. Cen Zhang
  5. Jianming Wang
  6. Jun Li
  7. Xiaohui Sun
  8. Yiming Zhu
  9. Zhaohui Feng
  10. Wenwei Hu
(2018)
A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models
eLife 7:e34701.
https://doi.org/10.7554/eLife.34701

Share this article

https://doi.org/10.7554/eLife.34701

Further reading

    1. Cancer Biology
    2. Genetics and Genomics
    Hirokazu Kimura, Kamel Lahouel ... Nicholas Jason Roberts
    Research Article

    Interpretation of variants identified during genetic testing is a significant clinical challenge. In this study, we developed a high-throughput CDKN2A functional assay and characterized all possible human CDKN2A missense variants. We found that 17.7% of all missense variants were functionally deleterious. We also used our functional classifications to assess the performance of in silico models that predict the effect of variants, including recently reported models based on machine learning. Notably, we found that all in silico models performed similarly when compared to our functional classifications with accuracies of 39.5–85.4%. Furthermore, while we found that functionally deleterious variants were enriched within ankyrin repeats, we did not identify any residues where all missense variants were functionally deleterious. Our functional classifications are a resource to aid the interpretation of CDKN2A variants and have important implications for the application of variant interpretation guidelines, particularly the use of in silico models for clinical variant interpretation.

    1. Cancer Biology
    2. Developmental Biology
    Sara Jaber, Eliana Eldawra ... Franck Toledo
    Research Article

    Missense ‘hotspot’ mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here, we generated Trp53Y217C, a mouse model of the human hotspot mutant TP53Y220C. DNA damage responses were lost in Trp53Y217C/Y217C (Trp53YC/YC) cells, and Trp53YC/YC fibroblasts exhibited increased chromosome instability compared to Trp53-/- cells. Furthermore, Trp53YC/YC male mice died earlier than Trp53-/- males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in Trp53YC/YC thymic cells compared to Trp53-/- cells. Surprisingly, we recovered only one Trp53YC/YC female for 22 Trp53YC/YC males at weaning, a skewed distribution explained by a high frequency of Trp53YC/YC female embryos with exencephaly and the death of most Trp53YC/YC female neonates. Strikingly, however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12), we observed a fivefold increase in the proportion of viable Trp53YC/YC weaned females in their progeny. Together, these data suggest that the p53Y217C mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females.